Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 11

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 11
---
 you may lose all or part of your investment. The occurrence of any of these risks might cause you to lose all or part of your
investment in the offered securities. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial.

3

USE OF PROCEEDS

We will not receive any proceeds from any sale of shares of our common stock by the selling stockholders or their permitted transferees. All proceeds from the
sale of shares of common stock will be for the accounts of the selling stockholders or their permitted transferees.

We will only receive net proceeds to
the extent that the Warrants are exercised for cash. We expect to use any such net proceeds from the exercise of the Warrants for general corporate purposes.

Our expected use of proceeds described above represents our current intentions based on our present plans and business condition. The amounts and timing of
our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned clinical trials, the results of our planned clinical trials, and other factors described in “Risk Factors” in this
prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs.

We will bear the out-of-pocket costs, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than
registration-related expenses, the selling stockholders will bear their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related
thereto.

4

PRIVATE PLACEMENT

The shares of common stock, Pre-Funded Warrants and Common Warrants being registered hereunder were issued in the
March PIPE Financing pursuant to the Purchase Agreement, among us and the Purchasers.

Exercise Price. The exercise price of each Prefunded Warrant
is $0.001 per share of common stock.

The initial exercise price of each Series A Warrant is $1.32 per share of common stock, subject to the
“reset” provision described below.

The initial exercise price of each Series B Warrant is $1.98 per share of common stock, subject to the
“reset” provision described below, or pursuant to a zero exercise price option, which is referred to in the Series B Warrant as an “alternative cashless exercise.”

Reset Provision.The exercise price of each of the Series A Warrants and Series